Capital International Investors Has $2.59 Billion Stake in Bristol-Myers Squibb (NYSE:BMY)

Capital International Investors increased its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,866,624 shares of the biopharmaceutical company’s stock after purchasing an additional 3,218,865 shares during the period. Capital International Investors’ holdings in Bristol-Myers Squibb were worth $2,593,940,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in BMY. Capital International Sarl lifted its holdings in shares of Bristol-Myers Squibb by 31.7% during the fourth quarter. Capital International Sarl now owns 154,092 shares of the biopharmaceutical company’s stock worth $8,715,000 after buying an additional 37,067 shares in the last quarter. First Commonwealth Financial Corp PA bought a new position in Bristol-Myers Squibb during the fourth quarter worth about $227,000. Demars Financial Group LLC acquired a new stake in Bristol-Myers Squibb in the 4th quarter worth about $49,866,000. MSH Capital Advisors LLC bought a new stake in Bristol-Myers Squibb in the 4th quarter valued at about $534,000. Finally, Zacks Investment Management raised its position in shares of Bristol-Myers Squibb by 4,936.4% in the fourth quarter. Zacks Investment Management now owns 250,965 shares of the biopharmaceutical company’s stock valued at $14,195,000 after buying an additional 245,982 shares in the last quarter. 76.41% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, EVP Samit Hirawat purchased 1,823 shares of the firm’s stock in a transaction dated Friday, February 14th. The stock was bought at an average price of $54.84 per share, with a total value of $99,973.32. Following the completion of the purchase, the executive vice president now owns 63,932 shares in the company, valued at approximately $3,506,030.88. This represents a 2.94 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. 0.07% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

BMY has been the subject of several analyst reports. Truist Financial lifted their price objective on Bristol-Myers Squibb from $62.00 to $65.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. UBS Group reduced their price objective on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating on the stock in a research note on Friday, April 11th. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an “equal weight” rating in a research report on Friday, February 7th. Cantor Fitzgerald increased their price target on shares of Bristol-Myers Squibb from $50.00 to $55.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Finally, The Goldman Sachs Group restated a “neutral” rating and set a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating, four have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $57.67.

Bristol-Myers Squibb Stock Performance

Shares of BMY stock opened at $49.24 on Friday. The firm has a market capitalization of $100.18 billion, a price-to-earnings ratio of -11.14, a PEG ratio of 2.07 and a beta of 0.41. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The business’s 50-day moving average price is $57.11 and its 200-day moving average price is $56.66. Bristol-Myers Squibb has a 12 month low of $39.35 and a 12 month high of $63.33.

Bristol-Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 EPS for the quarter, topping the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. Equities research analysts forecast that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Investors of record on Friday, April 4th will be issued a $0.62 dividend. The ex-dividend date of this dividend is Friday, April 4th. This represents a $2.48 dividend on an annualized basis and a yield of 5.04%. Bristol-Myers Squibb’s payout ratio is -56.11%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.